TY  - BOOK
AU  - Pasieka, Helena B
TI  - Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. [Review]
SN  - 0190-9622
PY  - 2020///
KW  - *Coronavirus Infections/pc [Prevention & Control]
KW  - *Dermatology/st [Standards]
KW  - *Immunosuppression/st [Standards]
KW  - *Pandemics/pc [Prevention & Control]
KW  - *Pneumonia, Viral/pc [Prevention & Control]
KW  - *Practice Guidelines as Topic
KW  - *Skin Diseases/th [Therapy]
KW  - Advisory Committees/st [Standards]
KW  - Betacoronavirus/im [Immunology]
KW  - Betacoronavirus/py [Pathogenicity]
KW  - Clinical Decision-Making
KW  - Coronavirus Infections/ep [Epidemiology]
KW  - Coronavirus Infections/im [Immunology]
KW  - Coronavirus Infections/vi [Virology]
KW  - Decision Making, Shared
KW  - Dermatologists/st [Standards]
KW  - Dermatology/mt [Methods]
KW  - Disease Susceptibility/im [Immunology]
KW  - Hospitalists/st [Standards]
KW  - Humans
KW  - Immunosuppression/ae [Adverse Effects]
KW  - Immunosuppression/mt [Methods]
KW  - Interdisciplinary Communication
KW  - Pneumonia, Viral/ep [Epidemiology]
KW  - Pneumonia, Viral/im [Immunology]
KW  - Pneumonia, Viral/vi [Virology]
KW  - Skin Diseases/im [Immunology]
KW  - Societies, Medical/st [Standards]
KW  - Symptom Flare Up
KW  - MedStar Washington Hospital Center
KW  - Dermatology
KW  - Journal Article
KW  - Review
N2  - Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of  the SARS-CoV-2 pandemic. Though the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of  such agents in COVID-19 are scarce. This article reviews and offers guidance based upon currently available safety data, and the most recent COVID-19  outcome data, in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasize a stepwise, shared decision-making  approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while  simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic. Copyright (c) 2020 American Academy of Dermatology, Inc. Published by  Elsevier Inc. All rights reserved
UR  - https://dx.doi.org/10.1016/j.jaad.2020.06.051
ER  -